Skip to content
Clinical Trials – home
LatviaBack to Latvia

Clinical trials in Jelgava – page 16

210 clinical trials in Jelgava, Latvia. Every trial is listed in the EU Clinical Trials Register and updated daily.

LatviaOur site in LatviaKliniskiePetijumi.lv(opens in a new tab)
Jelgava at a glance
210
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

210 trials in Jelgava

Open in trial search

Plasma cell myeloma+13

Not recruiting

Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Children with Multiple Sclerosis

Registered drug
Countries:LatviaLatvia
  • Participants:0–17 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Study on Batoclimab for Patients with Thyroid Eye Disease

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Short stature+3

Not recruiting

Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Study of Pembrolizumab with Chemotherapy for Patients with Resectable Stage II, IIIA, and IIIB Non-Small Cell Lung Cancer

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on LSTA1 and Temozolomide for Patients with Newly Diagnosed Glioblastoma Multiforme

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:LSTA1
  • Sponsor:Tartu University Hospital

Study Comparing Pembrolizumab Alone and with Sacituzumab Govitecan for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Crohn's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Diabetic retinal oedema+4

Not recruiting

Study on the Safety and Use of AVT06 (Aflibercept) for Patients with Chorioretinal Vascular Diseases

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Alvotech Swiss AG

Asthma

Not recruiting

Study on the Effectiveness and Safety of Tanimilast for Patients with Uncontrolled Asthma on Inhaled Corticosteroid and Long-Acting Beta2-Agonist Therapy

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Tanimilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Stage III Non-Small Cell Lung Cancer

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Latvia

The busiest research cities in the country

All 18 cities in Latvia

Clinical research in Jelgava

What the registry says about research in the country

01 Diabetes Management Studies

Clinical investigations focusing on type 2 diabetes management through combination therapy approaches. Research evaluates the effectiveness of gliclazide MR when combined with existing treatments.

  • Treatment Optimization
  • Glycemic Control
  • Combination Therapy

Studies aim to improve blood sugar control in patients not achieving optimal results with current medications.

02 Diabetic Eye Disease Research

Groundbreaking research examining the impact of semaglutide on diabetic retinopathy in patients with type 2 diabetes. This long-term safety study evaluates treatment effects on eye health.

  • Retinopathy Development
  • Disease Progression
  • Ophthalmologic Assessment

The research includes standardized ophthalmic evaluations to monitor disease progression and treatment outcomes.

03 Therapeutic Safety Studies

Post-authorization safety assessments conducted under European Medicines Agency oversight, focusing on long-term effects of diabetes treatments.

  • Safety Monitoring
  • Long-term Outcomes
  • Treatment Effects

These studies contribute to understanding the complete safety profile of new diabetes medications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.